February 25, 2015
2 min read
Save

Infants with certain congenital defects, genetic variant show better postsurgical outcomes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A minor allele of vascular endothelial growth factor A was associated with improved survival after surgery for congenital heart disease in infants, and the mechanism appears to be preservation of ventricular function.

Perspective from David Goldberg, MD

Previous research demonstrated that the minor allele of vascular endothelial growth factor A (VEGFA) single nucleotide polymorphism rs833069 was linked to improved transplant-free survival in infants who underwent surgery for congenital heart disease, but the biological mechanism was not known.

Researchers hypothesized that the minor allele would be related to better systemic function after surgery. They analyzed 422 nonsyndromic patients with congenital heart disease who underwent cardiac surgery with cardiopulmonary bypass before age 6 months at The Children’s Hospital of Philadelphia. They presented the findings at Cardiology 2015: The 18th Annual Update on Pediatric and Congenital Cardiovascular Disease.

Constantine D. Mavroudis, MD, MSc

Constantine D. Mavroudis

Constantine D. Mavroudis, MD, MSc, and colleagues reviewed echocardiography reports and calculated change in ventricular function from preoperative study to last available study.

Genetic and echocardiographic data were available for 335 of the 422 patients, of whom 9.9% developed worse systemic ventricular function during a mean follow-up of 13.5 years.

After adjustment for covariates, the VEGFA single nucleotide polymorphism rs833069 was associated with preserved ventricular function (P = .011), and a decrease in systemic ventricular function was associated with subsequent heart transplantation or death (P < .01).

“This has the potential to completely change the way that we’re tailoring genetic counseling and surgical options for a pretty sizable group of patients who have critical congenital heart disease that requires operative intervention in the first 6 months of life,” said Mavroudis, cardiac surgical resident at the Hospital of the University of Pennsylvania. – by Erik Swain

References:

Kim DS, et al. Ann Thorac Surg. 2014;doi:10.1016/j.athoracsur.2014.03.017.

Mavroudis CD, et al. Abstract 923. Presented at: Cardiology 2015: The 18th Annual Update on Pediatric and Congenital Cardiovascular Disease; Feb. 11-15, 2015; Scottsdale, Ariz.

Disclosure: Mavroudis reports no relevant financial disclosures.